Daily Endocrinology Research Analysis
Analyzed 90 papers and selected 3 impactful papers.
Summary
Analyzed 90 papers and selected 3 impactful articles.
Selected Articles
1. The E3 Ligase RNF8 Promotes Ubiquitination and Degradation of ChREBPα During Liver Stress Response.
Combined palmitate/TNFα stress triggers JNK2-dependent RNF8-mediated ubiquitination and proteasomal degradation of hepatocyte ChREBPα. Genetic depletion of JNK2 or RNF8 stabilizes ChREBPα in mouse liver and mitigates steatosis, inflammation, and fibrosis, nominating RNF8–ChREBPα as a therapeutic axis for MASH.
Impact: This study identifies a stress-inducible E3 ligase (RNF8) that directly governs ChREBPα proteolysis, linking metabolic/inflammatory stress to transcriptional control in MASH. It proposes a mechanistically precise therapeutic target with in vivo validation.
Clinical Implications: Although preclinical, inhibiting RNF8-mediated ChREBPα ubiquitination or modulating JNK2–RNF8 signaling could preserve hepatocyte metabolic programming, offering a novel avenue for MASH therapy beyond lipid-lowering and anti-inflammatory strategies.
Key Findings
- Combined palmitate and TNFα stress induces ubiquitination and proteasomal degradation of ChREBPα in hepatocytes.
- RNF8 is identified as the E3 ligase promoting ChREBPα ubiquitination in a JNK2-dependent manner.
- Acute hepatic depletion of JNK2 or RNF8 stabilizes ChREBPα in vivo and reduces diet-induced steatosis, inflammation, and fibrosis.
Methodological Strengths
- Integrated in vitro hepatocyte stress model with in vivo genetic depletion to establish causality.
- Mechanistic dissection of E3 ligase–substrate interaction with pathway dependency (JNK2) and phenotypic liver outcomes.
Limitations
- Preclinical mouse models may not capture human MASH heterogeneity and long-term safety of pathway modulation.
- Not all ChREBPα target genes increased upon stabilization, indicating context-specific transcriptional effects.
Future Directions: Develop small-molecule or peptide inhibitors that selectively disrupt RNF8–ChREBPα interaction; assess liver-specific delivery and pharmacodynamic biomarkers; validate translational relevance in human hepatocyte systems and MASH biopsies.
As the most common chronic liver disease, MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH) driven by accumulated metabolic and inflammatory stresses. We previously reported that liver ChREBPα protein is markedly downregulated in mouse models of diet-induced MASH and hepatotoxin-induced liver injury. Yet the impact of stress pathways on hepatocyte ChREBPα proteolysis has not been examined. Here, we show that a combined metabolic (palmitate, PA) and inflammatory (TNFα) stress signal promotes ubiquitination and proteasome-mediated degradation of ChREBPα in hepatocytes. More importantly, we identify the stress-induced E3 ligase RNF8 as interacting with and promoting ChREBPα ubiquitination and degradation in a JNK2-dependent manner. In vivo, acute depletion of JNK2 or RNF8 stabilizes ChREBPα in mouse liver, increases some but not all ChREBPα transcriptional targets, and reduces diet-induced liver steatosis, inflammation, and fibrosis. Overall, our findings reveal the biochemical machinery underlying stress-induced ChREBPα proteolysis and suggest that targeting RNF8-mediated ChREBPα ubiquitination could be a new strategy for treating MASH.
2. Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.
Using ML‑NMR across SURMOUNT‑1 and OASIS 1, tirzepatide 10/15 mg achieved significantly greater percentage weight and waist reductions than oral semaglutide 50 mg, with higher odds of achieving ≥5–20% weight loss. Cardiometabolic outcomes and safety were improved or comparable.
Impact: Head-to-head trials do not exist; this robust indirect comparison informs therapy selection between an injectable dual incretin and a high-dose oral GLP-1 RA for obesity management.
Clinical Implications: For adults without diabetes seeking maximal weight loss, tirzepatide 10–15 mg is likely to deliver superior weight and waist reduction versus oral semaglutide 50 mg, supporting shared decision-making that balances efficacy against route of administration and patient preference.
Key Findings
- Tirzepatide 10 mg and 15 mg reduced body weight by an additional 4.48% and 5.59% versus oral semaglutide 50 mg.
- Waist circumference decreased by 3.60 cm (10 mg) and 4.32 cm (15 mg) more than with oral semaglutide.
- Odds of achieving ≥5%, 10%, 15%, and 20% weight loss were higher with tirzepatide; cardiometabolic outcomes and safety were improved or comparable.
Methodological Strengths
- Multilevel network meta-regression adjusting for cross-trial baseline differences (sex, ethnicity, outcomes).
- Use of pivotal, long-duration RCTs (SURMOUNT‑1, OASIS 1) ensuring robust comparative anchors.
Limitations
- Indirect comparison; residual confounding from unmeasured cross-trial differences remains possible.
- Heterogeneity in trial designs and rescue interventions; no direct assessment of long-term safety beyond 68–72 weeks.
Future Directions: Head-to-head RCTs of tirzepatide versus oral semaglutide with patient-reported outcomes and cost-effectiveness; real-world comparative effectiveness stratified by adherence and tolerability.
AIMS: Tirzepatide, an injectable glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP-1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations. Currently, no studies have compared the efficacy and safety of tirzepatide with oral semaglutide for weight management. This study aimed to indirectly compare the efficacy and safety of weekly injectable tirzepatide 5, 10 and 15 mg for weight management in obesity and overweight versus daily oral semaglutide 50 mg. MATERIALS AND METHODS: Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations. Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m RESULTS: Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: -4.48% [-6.35, -2.61] and -5.59% [-7.52, -3.77]) and waist circumference (-3.60 cm [-5.59, -1.72] and -4.32 cm [-6.30, -2.40]), and higher odds of achieving ≥ 5%/10%/15%/20% weight reduction compared with oral semaglutide. Cardiometabolic benefits and safety profiles were improved or generally comparable for tirzepatide versus oral semaglutide. CONCLUSIONS: This ML-NMR provides an indirect comparison of injectable tirzepatide with oral semaglutide for weight management. Tirzepatide was associated with statistically significantly greater weight and waist circumference reduction versus oral semaglutide and improved or similar cardiometabolic benefits and safety.
3. Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation.
In a 1:1 propensity-matched, target trial emulation (n=169,630 per arm), GLP‑1 RA initiation versus DPP‑4i was associated with increased psoriasis risk and reduced risks of pemphigus and bullous pemphigoid over up to 4 years. Results were robust after excluding early protopathic events.
Impact: Provides high-powered, real-world, comparative safety data on dermatologic outcomes for incretin therapies, informing risk–benefit discussions and monitoring strategies.
Clinical Implications: When initiating GLP‑1 RAs, clinicians should counsel about and monitor for psoriasis while recognizing potential reductions in autoimmune blistering disease risk compared with DPP‑4 inhibitors; dermatologic history may guide incretin class selection.
Key Findings
- Propensity-matched cohorts (n=169,630 each) with up to 4-year follow-up showed GLP‑1 RAs increased incident psoriasis risk (HR 1.19).
- GLP‑1 RAs were associated with lower risks of pemphigus (HR 0.32) and bullous pemphigoid (HR 0.61) compared with DPP‑4 inhibitors.
- Protopathic bias was mitigated by excluding outcomes within 3 months of initiation; findings persisted in sensitivity and subgroup analyses.
Methodological Strengths
- Large-scale target trial emulation with 1:1 propensity score matching across comprehensive real-world data.
- Bias mitigation strategies including exclusion of early events and multiple sensitivity/subgroup analyses.
Limitations
- Residual confounding and misclassification inherent to observational EHR-based studies.
- Absolute risks were not reported; generalizability may vary by healthcare systems and coding practices.
Future Directions: Prospective pharmacovigilance with absolute risk estimates; mechanistic studies on GLP‑1 pathways in cutaneous immunity; stratified analyses by specific GLP‑1 agents and dosing.
BACKGROUND: While dipeptidyl peptidase-4 inhibitors (DPP-4is) are linked to autoimmune skin diseases, comparative data on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remain limited. METHODS: We emulated a randomized active-comparator trial using the TriNetX US Collaborative Network. Adults with type 2 diabetes (T2DM) initiating GLP-1 RAs or DPP-4is between January 1, 2018, and December 31, 2022, were identified, excluding prior users of either class. Balanced cohorts (n=169,630 each) were created using 1:1 propensity score matching. To address protopathic bias, outcomes occurring within 3 months after drug initiation were not considered. Patients were followed for up to 4 years for newly diagnosed autoimmune or inflammatory skin diseases. Cox regression estimated hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Compared with DPP-4i initiation, GLP-1 RA initiation was associated with a higher risk of incident psoriasis (HR 1.19, 95% CI 1.11-1.28) and lower risks of pemphigus (HR 0.32, 95% CI 0.16-0.63) and bullous pemphigoid (HR 0.61, 95% CI 0.43-0.87). No significant differences were observed for other inflammatory or autoimmune skin outcomes after multiple-testing correction. Findings persisted across subgroup and sensitivity analyses. CONCLUSION: In a large, real-world study designed to emulate a clinical trial, GLP-1 RAs were linked to increased psoriasis and decreased autoimmune blistering diseases compared with DPP-4is over up to 4 years' follow-up. These results provide a dermatologic safety context to guide incretin therapy selection and highlight the importance of ongoing skin monitoring.